@article{JTD26384,
author = {Jiro Ito and Kazuma Nagata and Takeshi Morimoto and Mariko Kogo and Daichi Fujimoto and Atsushi Nakagawa and Kojiro Otsuka and Keisuke Tomii},
title = {Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {1},
year = {2019},
keywords = {},
abstract = {Background: The role of high-flow nasal cannula oxygen therapy (HFNC) in respiratory management of acute exacerbation of interstitial pneumonia (AE-IP) is unknown.
Methods: We retrospectively reviewed patients with AE-IP who were admitted to our hospital from June 2009 – May 2015 and compared mortality, complications, sedatives and analgesia use, and oral intake between cohorts before (pre-HFNC: June 2009 – May 2012) and after (post-HFNC: June 2012 – May 2015) the introduction of HFNC. In the pre-HFNC cohort, standard oxygen therapy, noninvasive ventilation (NIV), and invasive mechanical ventilation (IMV) were used for respiratory management of AE-IP. In the post-HFNC cohort, HFNC was also used as an alternative to NIV in patients (I) who had refused NIV; (II) unable to cooperate, (III) intolerant to NIV, or (IV) who improved in respiratory parameters after NIV treatment for weaning.
Results: Fifty-three pre-HFNC patients and 43 post-HFNC patients were enrolled. Neither the baseline characteristics at admission nor the major pharmacotherapy for AE-IP differed between the two cohorts. Twenty-eight (52.8%) patients and 19 (44.2%) patients required any respiratory support, in pre- and post-HFNC cohort, respectively (P=0.40). After introduction of HFNC, it was used in 40% of the patients who required respiratory support and NIV use was significantly reduced from 49.1% to 16.3% (P24 hours were decreased after the introduction of HFNC (78.6% vs. 31.6%, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/26384}
}